Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.85 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.85 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.85 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.85 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.85 |
| ▸ | MAPT | P10636 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.85 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.85 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.85 |
| ▸ | HPGD | P15428 | 1/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.85 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.85 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.85 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-431542 SCHEMBL30033986 | 1.00 | TGFBR1 (0.85) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL29353092 | 1.00 | TGFBR1 (0.85) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL21046666 | 0.99 | TGFBR1 (0.84) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL29504865 | 0.99 | TGFBR1 (0.84) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| SCHEMBL22857113 | 0.94 | TGFBR1 (0.85) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL29359059 | 0.92 | TGFBR1 (1.00) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL29381798 | 0.92 | TGFBR1 (1.00) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL310028 | 0.92 | TGFBR1 (1.00) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL2681356 | 0.91 | TGFBR1 (0.98) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL29432843 | 0.91 | TGFBR1 (0.98) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367321-A1 | COMPOSITIONS AND METHODS INVOLVING ADGRG6 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-04 | — | — | US | claimed |
| WO-2023250130-A2 | COMPOSITIONS AND METHODS INVOLVING ADGRG6 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-12-28 | — | — | WO | claimed |
| US-11655450-B2 | Method for inducing differentiation of stem cell into dopaminergic neural precursor cell | S-BIOMEDICS (KR) | 2023-05-23 | — | — | US | claimed |
| US-20210238547-A1 | Method For Inducing Differentiation Of Stem Cell Into Dopaminergic Neural Precursor Cell | S-BIOMEDICS (KR) | 2021-08-05 | — | — | US | claimed |
| WO-2021060637-A1 | METHOD FOR INDUCING DIFFERENTIATION INTO DOPAMINE NEURONAL PRECURSOR CELLS FROM STEM CELLS | (주) 에스바이오메딕스 | 2021-04-01 | — | — | WO | claimed |
| US-20200276166-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | UNIV CALIFORNIA (US) | 2020-09-03 | — | — | US | claimed |
| EP-2502987-B1 | EFFICIENT AND UNIVERSAL METHOD FOR INDUCING THE DIFFERENTIATION OF NERVE CELLS FROM PLURIPOTENT STEM CELLS | S BIOMEDICS (KR) | 2018-05-16 | — | — | EP | claimed |
| US-20160367530-A1 | METHODS OF TREATING NEUROLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-22 | — | — | US | claimed |
| US-8551783-B2 | Efficient and universal method for neural differentiation of human pluripotent stem cells | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2013-10-08 | — | — | US | claimed |
| EP-2502987-A2 | EFFICIENT AND UNIVERSAL METHOD FOR INDUCING THE DIFFERENTIATION OF NERVE CELLS FROM PLURIPOTENT STEM CELLS | Industry-Academic Cooperation Foundation (KR) | 2012-09-26 | — | — | EP | claimed |
| US-20120058949-A1 | Methods of Treating Neurological Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-03-08 | — | — | US | claimed |
| US-20110217774-A1 | Efficient and Universal Method for Neural Differentiation of Pluripotent Stem Cells | INDUSTRY-ACADEMIC COOPERATION FOUNDATION YONSEI UNIVERSITY (KR) | 2011-09-08 | — | — | US | claimed |
| US-20090181420-A1 | Inhibiting Smad signaling promotes neuron regeneration | CHILDREN'S MEDICAL CENTER CORPORATION | 2009-07-16 | — | — | US | claimed |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-12516286-B2 | Method for producing dopaminergic neuron progenitor cell | KYOTO UNIVERSITY (JP) | 2026-01-06 | — | — | US | disclosed |
| US-20250367321-A1 | COMPOSITIONS AND METHODS INVOLVING ADGRG6 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-04 | — | — | US | disclosed |
| US-20080166327-A1 | Method for Amplification of Endothelial Progenitor Cell in Vitro | STEMMED INC. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| US-20080031911-A1 | Inhibiting smad signaling promotes neuron regeneration | CHILDREN'S MEDICAL CENTER CORPORATION, DUKE UNIVERSITY | 2008-02-07 | — | — | US | disclosed |
| EP-1860180-A1 | METHOD FOR AMPLIFICATION OF ENDOTHELIAL PROGENITOR CELL IN VITRO | Foundation for Biomedical Research and Innovation (JP) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | TGFBR1 4740/4885CSNK1A1 2320/4885CSNK1D 2327/4885 |
| US-20260049159-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, CD2, TGFBR2 | TGFBR1 5/4885CSNK1A1 3066/4885CSNK1D 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.